The subsidiary of HZPHARM (600267.SH), the formulation product Phosphoryl Fluoridatabine Injection, has obtained approval from the US FDA.

Wisdom Financial News APP, HZPHARM (600267.SH) announced that recently, its wholly-owned subsidiary HZPHARM (Hangzhou) Co., Ltd. (referred to as "HZPHARM Hangzhou Company") has received notification from the US Food and Drug Administration (FDA) that the Abbreviated New Drug Application (ANDA) for Fluorouracil Injection filed by HZPHARM Hangzhou Company has been approved, which means that the company can now sell this product in the US market.